Opioids
The Food and Drug Administration Friday approved the first generic naloxone nasal spray, an emergency treatment for opioid overdose intended for use in the community. Generic injectable naloxone products have been available for use in health care settings for years.
April 27 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired prescription pills at sites throughout the country.
The National Institutes of Health today selected several universities to partner with communities in Kentucky, Massachusetts, New York and Ohio to study the impact of integrating evidence-based interventions to prevent and treat opioid addiction,
The latest Advancing Health podcast from the AHA features Dr. Stephen Patrick, an attending neonatologist at Monroe Carell Jr. Children’s Hospital at Vanderbilt and director of the Vanderbilt Center for Child Health Policy, who shares how his system is working to improve outcomes for opioid-exposed…
The Food and Drug Administration yesterday announced changes to the prescribing information included in outpatient opioid pain medication labels.
The Agency for Healthcare Research and Quality is accepting comments through April 25 on a draft report on treatment for acute pain.
Presbyterian Healthcare Services – Albuquerque, NM
Holistic Partnership Improves Outcomes for Patients with Substance Use Disorders
Presbyterian Healthcare Services started a statewide partnership, called The Substance Use Disorder and Community Collaborative Initiative, in 2017 to deliver…
The Department of Health and Human Services this week awarded $487 million in fiscal year 2019 grants to help states and territories increase access to medication-assisted treatment for opioid use disorder and reduce opioid overdose deaths.
The three medications approved by the Food and Drug Administration to treat opioid use disorder — methadone, buprenorphine and extended-release naltrexone — are effective and save lives, but most people who could benefit from these treatments do not receive them, according to a report released…
In a study of Blue Cross and Blue Shield enrollees reported last week in the New England Journal of Medicine, initial opioid prescriptions declined 54 percent between July 2012 and December 2017.